title: Antibiotic treatment for children hospitalized with community-acquired pneumonia after oral therapy.
abstract: OBJECTIVE
  To compare the outcome of treatment with narrow spectrum versus broad spectrum antibiotics in children hospitalized with community-acquired pneumonia (CAP) who received oral antibiotic treatment prior to their hospitalization.
  
  
  METHODS
  A review of all previously healthy children from 3 months to 18 years with non-complicated CAP who received an oral antibiotic course in the community and were admitted from 2003 to 2008 to our pediatric departments.
  
  
  METHODS
  Clinical course and outcome parameters were compared for treatment with narrow and broad spectrum antibiotics.
  
  
  RESULTS
  Of the 337 children admitted with non-complicated CAP after an oral antibiotic treatment course in the community, 235 were treated with broad spectrum, and 102 with narrow spectrum antibiotics. The two groups were similar regarding age, sex, days of fever prior to admission, type of preadmission oral antibiotic treatment, and laboratory indices at admission (P > 0.1). The broad spectrum-treated group had significantly better outcomes in terms of number of febrile days (1.2 ± 1.1 vs. 1.7 ± 1.6, P < 0.001), number of days treated with intravenous antibiotics (3.1 ± 1.3 vs. 3.9 ± 2.0, P < 0.001), and days of hospitalization (3.5 ± 1.5 vs. 4.2 ± 2.0, P < 0.001). The odds ratio for remaining hospitalized at 72 hr and 7 days was significantly higher for the narrow spectrum group (2.0 and 5.5 respectively, P < 0.05).
  
  
  CONCLUSIONS
  In previously healthy children hospitalized with CAP after oral antibiotic treatment in the community treatment with broad spectrum antibiotics showed better outcome. Prospective studies are needed for appropriate recommendation.
authors: Pediatric Pulmonology, Departments of Pediatrics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
authors: Oded
authors: O
authors: Breuer
authors: Ori
authors: O
authors: Blich
authors: Malena
authors: M
authors: Cohen-Cymberknoh
authors: Diana
authors: D
authors: Averbuch
authors: Sigmund
authors: S
authors: Kharasch
authors: David
authors: D
authors: Shoseyov
authors: Eitan
authors: E
authors: Kerem
mesh_terms: D061605:Administration, Intravenous; D000284:Administration, Oral; D000293:Adolescent; D000553:Ambulatory Care; D000658:Amoxicillin / Q000627:therapeutic use; D000667:Ampicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002437:Cefazolin / Q000627:therapeutic use; D002443:Ceftriaxone / Q000627:therapeutic use; D002444:Cefuroxime / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D017714:Community-Acquired Infections / Q000188:drug therapy; D005260:Female; D005334:Fever; D006760:Hospitalization; D006801:Humans; D007223:Infant; D007902:Length of Stay; D016014:Linear Models; D016015:Logistic Models; D008297:Male; D015999:Multivariate Analysis; D010406:Penicillins / Q000627:therapeutic use; D018410:Pneumonia, Bacterial / Q000188:drug therapy*; D012189:Retrospective Studies
chemical_list: D000900:Anti-Bacterial Agents; D010406:Penicillins; D002443:Ceftriaxone; D000667:Ampicillin; D000658:Amoxicillin; D002437:Cefazolin; D002444:Cefuroxime
keywords: antibiotics; community-acquired pneumonia; nonresponsive; pediatrics